Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erica L Mayer

Showing results (41-50 of 120) with videos related to

Pageof 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2011
A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancerErica L Mayer, Jean-Francois Baurain, Joseph Sparano, et al.
Breast Cancer Research and Treatment|September 25, 2012
Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomicsErica L Mayer, Steven J Isakoff, Giannoula Klement, et al.
Clinical Breast Cancer|October 27, 2024
Effective Strategies for the Prevention and Mitigation of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia: Optimizing Patient CareHeather N Moore, Marcus D Goncalves, Abigail M Johnston, et al.
Springerplus|July 27, 2013
Contemporary multidisciplinary treatment of pregnancy-associated breast cancerJane L Meisel, Katherine E Economy, Katherina Zabicki Calvillo, et al.
Breast Cancer Research and Treatment|April 22, 2024
Racial disparities in outcomes of patients with stage I-III triple-negative breast cancer after adjuvant chemotherapy: a post-hoc analysis of the E5103 randomized trialSaskia Leonard, Alyssa N Jones, Lisa Newman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2011
Congestive heart failure risk in patients with breast cancer treated with bevacizumabToni K Choueiri, Erica L Mayer, Youjin Je, et al.
Annals of Surgical Oncology|September 5, 2023
Racial Disparities in Locoregional Recurrence in Postmenopausal Patients with Stage I-III, Hormone Receptor-Positive Breast Cancer Enrolled in the NSABP B-42 Clinical TrialCharity C Glass, Robert M Pride, Rachel A Freedman, et al.
Breast Cancer Research and Treatment|August 4, 2025
Assessing racial disparities in disease outcomes of patients with high-risk, triple-negative breast cancer and residual disease after neoadjuvant therapy: a post-hoc analysis of the ECOG-ACRIN 1131 clinical trialKate Lloyd, Lisa A Newman, Charity Glass, et al.
The Oncologist|December 20, 2024
Incidence of patient-reported fatigue developing on palbociclib and endocrine therapy for advanced HR+ HER2- breast cancerShadab A Rahman, Hanneke Poort, Deborah Schrag, et al.
Clinical Breast Cancer|September 11, 2014
Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancerErica L Mayer, Adrienne B Gropper, Lyndsay Harris, et al.
Pageof 12

Showing results (41-50 of 120) with videos related to

Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2011
A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancerErica L Mayer, Jean-Francois Baurain, Joseph Sparano, et al.
Breast Cancer Research and Treatment|September 25, 2012
Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomicsErica L Mayer, Steven J Isakoff, Giannoula Klement, et al.
Clinical Breast Cancer|October 27, 2024
Effective Strategies for the Prevention and Mitigation of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia: Optimizing Patient CareHeather N Moore, Marcus D Goncalves, Abigail M Johnston, et al.
Springerplus|July 27, 2013
Contemporary multidisciplinary treatment of pregnancy-associated breast cancerJane L Meisel, Katherine E Economy, Katherina Zabicki Calvillo, et al.
Breast Cancer Research and Treatment|April 22, 2024
Racial disparities in outcomes of patients with stage I-III triple-negative breast cancer after adjuvant chemotherapy: a post-hoc analysis of the E5103 randomized trialSaskia Leonard, Alyssa N Jones, Lisa Newman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2011
Congestive heart failure risk in patients with breast cancer treated with bevacizumabToni K Choueiri, Erica L Mayer, Youjin Je, et al.
Annals of Surgical Oncology|September 5, 2023
Racial Disparities in Locoregional Recurrence in Postmenopausal Patients with Stage I-III, Hormone Receptor-Positive Breast Cancer Enrolled in the NSABP B-42 Clinical TrialCharity C Glass, Robert M Pride, Rachel A Freedman, et al.
Breast Cancer Research and Treatment|August 4, 2025
Assessing racial disparities in disease outcomes of patients with high-risk, triple-negative breast cancer and residual disease after neoadjuvant therapy: a post-hoc analysis of the ECOG-ACRIN 1131 clinical trialKate Lloyd, Lisa A Newman, Charity Glass, et al.
The Oncologist|December 20, 2024
Incidence of patient-reported fatigue developing on palbociclib and endocrine therapy for advanced HR+ HER2- breast cancerShadab A Rahman, Hanneke Poort, Deborah Schrag, et al.
Clinical Breast Cancer|September 11, 2014
Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancerErica L Mayer, Adrienne B Gropper, Lyndsay Harris, et al.
Pageof 12